Access the full text.
Sign up today, get DeepDyve free for 14 days.
M. Elshamaa, S. Sabry, E. Elghoroury, Gamila El-Saaid, D. Kandil (2010)
Serum Lipid Profile and Plasma Fatty Acids Levels in Hemodialysis Pediatric Patients-Possible Deficiency of Essential Fatty AcidsKidney, 19
M. Tsujimoto, K. Higuchi, D. Shima, H. Yokota, T. Furukubo, S. Izumi, T. Yamakawa, M. Otagiri, S. Hirata, K. Takara, K. Nishiguchi (2010)
Inhibitory effects of uraemic toxins 3‐indoxyl sulfate and p‐cresol on losartan metabolism in vitroJournal of Pharmacy and Pharmacology, 62
R. Vanholder, S. Laecke, G. Glorieux (2008)
What is new in uremic toxicity?Pediatric Nephrology (Berlin, Germany), 23
R. Palacharla, Venkatesham Uthukam, Arunkumar Manoharan, R. Ponnamaneni, N. Padala, R. Boggavarapu, Gopinadh Bhyrapuneni, D. Ajjala, R. Nirogi (2017)
Inhibition of cytochrome P450 enzymes by saturated and unsaturated fatty acids in human liver microsomes, characterization of enzyme kinetics in the presence of bovine serum albumin (0.1 and 1.0% w/v) and in vitro – in vivo extrapolation of hepatic clearanceEuropean Journal of Pharmaceutical Sciences, 101
Ken-Ichi Fujita, Y. Sunakawa, K. Miwa, Y. Akiyama, Minako Sugiyama, K. Kawara, H. Ishida, K. Yamashita, K. Mizuno, S. Saji, W. Ichikawa, W. Yamamoto, F. Nagashima, T. Miya, M. Narabayashi, Y. Ando, T. Hirose, Y. Sasaki (2011)
Delayed Elimination of SN-38 in Cancer Patients with Severe Renal FailureDrug Metabolism and Disposition, 39
T. Satoh, M. Hosokawa (2006)
Structure, function and regulation of carboxylesterases.Chemico-biological interactions, 162 3
J. Prusakiewicz, C. Ackermann, R. Voorman (2006)
Comparison of Skin Esterase Activities from Different SpeciesPharmaceutical Research, 23
A. Dreisbach, J. Lertora (2008)
The effect of chronic renal failure on drug metabolism and transportExpert Opinion on Drug Metabolism & Toxicology, 4
H. Inamoto, Ryoko Ozaki, Takako Matsuzaki, M. Wakui, T. Saruta, A. Osawa (1991)
Incidence and mortality patterns of malignancy and factors affecting the risk of malignancy in dialysis patients.Nephron, 59 4
D. Sica, C. Halstenson, T. Gehr, W. Keane (2000)
Pharmacokinetics and Blood Pressure Response of Losartan in End-Stage Renal DiseaseClinical Pharmacokinetics, 38
Y. Zhang, L. Zhang, S. Abraham, S. Apparaju, T‐C Wu, J. Strong, S. Xiao, A. Atkinson, K. Thummel, J. Leeder, C. Lee, G. Burckart, L. Lesko, S.-M. Huang (2009)
Assessment of the Impact of Renal Impairment on Systemic Exposure of New Molecular Entities: Evaluation of Recent New Drug ApplicationsClinical Pharmacology & Therapeutics, 85
M. Tsujimoto, Y. Kinoshita, S. Hirata, M. Otagiri, H. Ohtani, Y. Sawada (2008)
Effects of Uremic Serum and Uremic Toxins on Hepatic Uptake of DigoxinTherapeutic Drug Monitoring, 30
K. Hanada, Rie Ogawa, K. Son, Y. Sasaki, A. Kikkawa, Shiho Ichihara, H. Ogata (2006)
Effects of Indoxylsulfate on the in vitro Hepatic Metabolism of Various Compounds Using Human Liver Microsomes and HepatocytesNephron Physiology, 103
K. Shirai, I. Ohsawa, Y. Saito, S. Yoshida (1988)
Effects of phospholipids on hydrolysis of trioleoylglycerol by human serum carboxylesterase.Biochimica et biophysica acta, 962 3
F. Jong, J. Bol, R. Mathijssen, T. Gelder, E. Wiemer, A. Sparreboom, A. Sparreboom, Jaap Verweij (2008)
Renal Function as a Predictor of Irinotecan‐induced NeutropeniaClinical Pharmacology & Therapeutics, 84
M. Hatfield, L. Tsurkan, M. Garrett, Timothy Shaver, J. Hyatt, C. Edwards, Latorya Hicks, Philip Potter (2011)
Organ-specific carboxylesterase profiling identifies the small intestine and kidney as major contributors of activation of the anticancer prodrug CPT-11.Biochemical pharmacology, 81 1
C. Muller, S. Caillard, L. Jesel, S. ghannudi, P. Ohlmann, E. Sauleau, T. Hannedouche, C. Gachet, B. Moulin, O. Morel (2012)
Association of estimated GFR with platelet inhibition in patients treated with clopidogrel.American journal of kidney diseases : the official journal of the National Kidney Foundation, 59 6
Manlio Palumbo, C. Sissi, Barbara Gatto, Stefano Moro, G. Zagotto (2001)
Quantitation of camptothecin and related compounds.Journal of chromatography. B, Biomedical sciences and applications, 764 1-2
A. Butler, A. Olshan, A. Kshirsagar, Jessie Edwards, M. Nielsen, S. Wheeler, M. Brookhart (2015)
Cancer incidence among US Medicare ESRD patients receiving hemodialysis, 1996-2009.American journal of kidney diseases : the official journal of the National Kidney Foundation, 65 5
Thomas Gibson (1986)
Renal disease and drug metabolism: an overview.American journal of kidney diseases : the official journal of the National Kidney Foundation, 8 1
J. Lewis, R. Horenstein, K. Ryan, J. O’Connell, Q. Gibson, B. Mitchell, K. Tanner, Sumbul Chai, K. Bliden, U. Tantry, C. Peer, W. Figg, S. Spencer, M. Pacanowski, P. Gurbel, A. Shuldiner (2013)
The functional G143E variant of carboxylesterase 1 is associated with increased clopidogrel active metabolite levels and greater clopidogrel responsePharmacogenetics and Genomics, 23
M. Tsujimoto, Sari Sugimoto, Makiko Nagatomo, T. Furukubo, S. Izumi, T. Yamakawa, T. Minegaki, K. Nishiguchi (2014)
Possibility of Decrease in CYP1A2 Function in Patients With End‐Stage Renal DiseaseTherapeutic Apheresis and Dialysis, 18
Hao‐Jie Zhu, Xinwen Wang, Brian Gawronski, B. Brinda, D. Angiolillo, J. Markowitz (2013)
Carboxylesterase 1 as a Determinant of Clopidogrel Metabolism and ActivationThe Journal of Pharmacology and Experimental Therapeutics, 344
J. Crow, K. Herring, Shuqi Xie, A. Borazjani, Philip Potter, Matthew Ross (2010)
Inhibition of carboxylesterase activity of THP1 monocytes/macrophages and recombinant human carboxylesterase 1 by oxysterols and fatty acids.Biochimica et biophysica acta, 1801 1
T. Imai (2006)
Human carboxylesterase isozymes: catalytic properties and rational drug design.Drug metabolism and pharmacokinetics, 21 3
E. Tarkiainen, M. Holmberg, A. Tornio, M. Neuvonen, P. Neuvonen, J. Backman, M. Niemi (2015)
Carboxylesterase 1 c.428G>A single nucleotide variation increases the antiplatelet effects of clopidogrel by reducing its hydrolysis in humansClinical Pharmacology & Therapeutics, 97
K. Yamaoka, Y. Tanigawara, T. Nakagawa, T. Uno (1981)
A pharmacokinetic analysis program (multi) for microcomputer.Journal of pharmacobio-dynamics, 4 11
G. Freyer, P. Rougier, R. Bugat, J. Droz, M. Marty, H. Bleiberg, D. Mignard, L. Awad, P. Hérait, S. Culine, V. Trillet‐Lenoir, F220 F205 (2000)
Prognostic factors for tumour response, progression-free survival and toxicity in metastatic colorectal cancer patients given irinotecan (CPT-11) as second-line chemotherapy after 5FU failureBritish Journal of Cancer, 83
S. Park, Weon Kim, C. Park, W. Kang, S. Hwang, Wan Kim (2009)
A comparison of clopidogrel responsiveness in patients with versus without chronic renal failure.The American journal of cardiology, 104 9
D. Czock, F. Rasche, B. Boesler, M. Shipkova, F. Keller (2009)
Irinotecan in Cancer Patients with End-Stage Renal FailureAnnals of Pharmacotherapy, 43
A. Sparreboom, M. Jonge, P. Bruijn, E. Brouwer, K. Nooter, W. Loos, R. Alphen, R. Mathijssen, G. Stoter, J. Verweij (1998)
Irinotecan (CPT-11) metabolism and disposition in cancer patients.Clinical cancer research : an official journal of the American Association for Cancer Research, 4 11
Yurie Katsube, M. Tsujimoto, Hiroyoshi Koide, Megumi Ochiai, Ayako Hojyo, Kaori Ogawa, K. Kambara, Naofumi Torii, D. Shima, T. Furukubo, S. Izumi, T. Yamakawa, T. Minegaki, K. Nishiguchi (2017)
Cooperative inhibitory effects of uremic toxins and other serum components on OATP1B1-mediated transport of SN-38Cancer Chemotherapy and Pharmacology, 79
J. Mukherjee, F. Jay, P. Choy (1993)
Purification, characterization and modulation of a microsomal carboxylesterase in rat liver for the hydrolysis of acyl-CoA.The Biochemical journal, 295 ( Pt 1)
Purpose Pharmacokinetics and pharmacodynamics of irinotecan have been reported to be altered in cancer patients with end-stage kidney disease (ESKD). Carboxylesterase (CES) has an important role in metabolism of irinotecan to its active metabolite, SN-38, in human liver. The purpose of the present study was to investigate whether CES activity was altered in ESKD patients. Methods The present study investigated the effects of uremic serum, uremic toxins, and fatty acids on the hydrolysis of irinotecan and a typical CES substrate, p-nitrophenyl acetate (PNPA), in human liver microsomes. Normal and uremic serum samples were deproteinized by treatment with methanol were used in the present study. Results The present study showed that both normal and uremic serum significantly inhibited CES-mediated metabolism of both irinotecan and PNPA. The inhibition by uremic serum was weaker than that by normal serum, suggesting that CES activity may be higher in ESKD patients. Although four uremic toxins did not affect PNPA metabolism, arachidonic acid inhibited it. There was no difference in inhibitory effect of PNPA metabolism between both mixtures of seven fatty acids used at concentrations equivalent to those present in 10% normal or uremic serum. Interestingly, those mixtures had a more pronounced effect than either
Cancer Chemotherapy and Pharmacology – Springer Journals
Published: Apr 24, 2018
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.